Literature DB >> 15575814

Hemianopic visual field loss as the first clinical evidence of occipital arteriovenous malformation.

Ian F Gutteridge1, Robert A McDonald.   

Abstract

A 43-year-old patient presenting with a highly congruous homonymous hemianopia was shown by neuro-imaging to have a very large arteriovenous malformation of the brain. The significance of finding this visual field defect, its unusual cause and the absence of symptoms other than longstanding migraine with aura are discussed.

Entities:  

Mesh:

Year:  2004        PMID: 15575814     DOI: 10.1111/j.1444-0938.2004.tb03101.x

Source DB:  PubMed          Journal:  Clin Exp Optom        ISSN: 0816-4622            Impact factor:   2.742


  5 in total

1.  Visual cortical activity reflects faster accumulation of information from cortically blind fields.

Authors:  Tim Martin; Anasuya Das; Krystel R Huxlin
Journal:  Brain       Date:  2012-11       Impact factor: 13.501

2.  Beyond blindsight: properties of visual relearning in cortically blind fields.

Authors:  Anasuya Das; Duje Tadin; Krystel R Huxlin
Journal:  J Neurosci       Date:  2014-08-27       Impact factor: 6.167

3.  Role of inter-hemispheric transfer in generating visual evoked potentials in V1-damaged brain hemispheres.

Authors:  Voyko Kavcic; Regina L Triplett; Anasuya Das; Tim Martin; Krystel R Huxlin
Journal:  Neuropsychologia       Date:  2015-01-07       Impact factor: 3.139

4.  Perceptual relearning of complex visual motion after V1 damage in humans.

Authors:  Krystel R Huxlin; Tim Martin; Kristin Kelly; Meghan Riley; Deborah I Friedman; W Scott Burgin; Mary Hayhoe
Journal:  J Neurosci       Date:  2009-04-01       Impact factor: 6.167

5.  Neurorehabilitation of saccadic ocular movement in a patient with a homonymous hemianopia postgeniculate caused by an arteriovenous malformation: A Case Report.

Authors:  Mirna Pineda-Ortíz; Gustavo Pacheco-López; Moisés Rubio-Osornio; Carmen Rubio; Juan Valadez-Rodríguez
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.